Pitch Perfect and Boost the EU Bioeconomy 2025
2025-11-24 08:00 - 2025-11-25 20:00 (Europe/Brussels)
Pitching, Matchmaking And Networking In The Heart Of Europe!

The ‘Pitch Perfect and Boost the European Bioeconomy’ event is a two day event of intense cross-border and cross-sectoral pitching, matchmaking and networking, with the aim to link industry to innovative (biobased) technologies, innovators to investors and to create new partnerships for the future and the further development of innovative, cross-border and cross-sectoral industrial value chains in the biobased economy.

More Info Here

EUCROF26
2026-02-01 08:00 - 2026-02-03 20:00
Building on the momentum of nearly 350 attendees at EUCROF25, EUCROF26 will once again bring together clinical research professionals from across Europe and beyond. Expect three days of high-impact networking, thought-provoking sessions, and future-focused dialogue designed to accelerate innovation and excellence in our field.

Join our Director General Claire Skentelbery from 1–3 February 2026 as we shape the next chapter of clinical research; together.

More Info Here

Navigating Biotech SME Funding: What's available, How it works, What's next for Europe
2026-03-10 10:00 - 11:00
Europe’s biotech sector continues to face significant financing challenges, especially during growth and scale‑up. As the EU moves forward with the landmark Biotech Act, this webinar explores the funding tools available today, how companies can access them, and what changes are needed to expand investment in European biotech.

The session will provide an overview of current EU public and blended finance options across the development pipeline, explain how the European Investment Bank evaluates and supports biotech projects, and offer first-hand insights from a biotech founder on securing funding from idea to market. It will also examine how upcoming EU initiatives could improve access to capital and attract more private investment.

Speakers include

Felicitas Riedl, Director of Innovation and Competitiveness at the European Investment Bank

Raffael Wohlgensinger, Founder & CEO, Formo

Jessica Martinsson, our moderator and CEO of SwedenBIO, the Swedish Biotech Association

Registration Here

BIO-Europe Spring 2026
2026-03-23 08:00 - 2026-03-25 20:00
EuropaBio is joining BIO-Europe Spring 2026.

BIO-Europe Spring is Europe’s largest springtime biotech partnering event, bringing together over 3,700 leaders and innovators in the life sciences industry. It’s designed for partnering, business development, and licensing opportunities in biotechnology and pharmaceuticals.

More Info Here

Special feature: Biotech Act Part I – Dr Claire Skentelbery, Director General EuropaBio @ BIO-Europe Spring 2026
2026-03-23 16:30 - 18:00
Join our Director General Dr Claire Skentelbery at BIO-Europe Spring on the 23rd of March for an afternoon session dedicated to the EU Biotech Act Part 1.

The EU Biotech Act represents a landmark piece of legislation aimed at positioning Europe as a global leader in biotech. Structured in two parts, the legislative program seeks to drive competitiveness across multiple sectors. Part I of the EU Biotech Act, published in December 2025, focuses on advancing health innovation. Key initiatives include accelerating clinical trials, extending intellectual property protections, launching a robust investment program, and introducing strategic projects designed to achieve critical mass in applied innovation. Part II, set to be unveiled in 2026, will shift the focus toward maximising biomanufacturing across industries, further strengthening Europe’s biotech ecosystem.

This feature session is dedicated to the Biotech Act part, including a Keynote and Fireside Chat.

16:30 Keynote presentation: Dr Claire Skentelbery, Director General EuropaBio

17:00 Fireside chat: Dr Claire Skentelbery in discussion with Dr Tilo Mandry, Lead International Liaison Manager IGES

17:15: Session: Special feature: Biotech Act Part I – What’s in it for me? Industry panel discussionPanelists:– Dr Morgane Rousselot, Founder, Chairwoman and CEO, SeaBeLife Biotech– Dr Ann Belien, Founder & CEO, Rejuvenate Biomed (tbc)– Andreas Prenner, Policy Officer, European Commission– Dr Marjo Puumalainen, International Director, SwedenBIO– Dr Tilo Mandry, Lead International Liaison Manager, IGES (Moderator)

This panel continues the EU Biotech Act Special Feature: We will discuss what the Biotech Act means for biotech companies and Europe as a biotech investment location, and how companies can best adapt to its provisions.

There are many questions about the Biotech Act:– How will industrial clinical research be accelerated and how will this affect the development of innovative therapies?– How will the Biotech Act impact the financing of innovative biotech start-ups?– Can cell and gene therapies now be developed more quickly by companies in the EU and brought to patients more easily?– What does the extension of intellectual property protection mean for biopharmaceutical companies in practice?– Is the Act sufficiently targeted at industry and where are the risk points?– And finally, can the EU compete globally, particularly with the US and China, thanks to the Biotech Act?We will discuss these and many other important aspects with the panelists and the audience.

18:00: Close

More Info Here

The EU Biotech Act: Europe’s ambition for biotechnology
2026-04-14 14:30 - 15:30
Join Director General Sandra Gallina and EuropaBio to explore the EU Biotech Act proposal, published in December 2025.

The webinar explores the Goal of the Act, to boost innovation, support development of biotech products and accelerate time-to-market, making use of industrial enablers and regulatory simplification.

This webinar will introduce the drivers behind the Biotech Act proposal plus its diverse and ambitious mechanisms to boost EU biotech delivery. It will discuss how mechanisms might work and the interlink of the Act with the wider European Legislative landscape, and its legislative pathway into action for the EU.

Webinar delegates will have the opportunity to ask Director General Gallina questions during the event and EuropaBio will publish a summary for all participants.

AGENDA

14h30: Introduction – Dr Claire Skentelbery, Director General EuropaBio

14h40: The Biotech Act in focus – Director General Sandra Gallina, DG Health and Food Safety, European Commission:

Regulatory streamlining and facilitation in health, food and other biotech

Industrial enablers including High Impact Strategic Projects, Boosting innovative biotech & biosimilars, Access to Finance, AI and Data, Biosecurity & Defence

15h10: Discussion and audience Q&A

15h30: Close

Who should attend? If you are active within biotechnology in any sector, you should attend to understand what the Act means for you, how you should be involved and what happens next.

Register below

Registration Here

AseBio Green Innovation Forum
2026-04-20 08:00 - 2026-04-21 20:00
AseBio announces the Green Innovation Forum2026, which will take place in Salamanca on 20–21 April 2026, positioning the city as a meeting point for green biotechnology, bioeconomy and sustainable innovation in Europe.The Green Innovation Forum is designed as a meeting point for business development, bringing together companies, startups, investors, technologycentres and institutions committed to accelerating the green transition through biotechnology. The previous 2024 edition brought together 216 participants, from 123 organisations represented and 195 one-to-one meetings, confirming the growing interest in this specialised forum.For the 2026 edition, the Green Innovation Forum strengthens its positioning by broadening its scope to further integrate the agrifood and foodtech sectors, reflecting their increasing convergence with green biotech, the bioeconomy and sustainable innovation. This evolution responds to the need for cross-sector collaboration to address global challenges.

More Info Here

BioSolutions UK
2026-04-21 08:00 - 20:00
Proud to support BioSolutions UK conference — a new platform bringing together leaders in engineering biology to accelerate growth, collaboration and real-world adoption.

Biosolutions are reshaping food, agriculture, chemicals, materials and biofuels, and we’re excited to back an event championing the innovators driving this transition and strengthening the UK’s position in the global bioeconomy.

Join us on 21 April 2026 in London.

More Info Here

CEBioForum 2026
2026-04-22 08:00 - 2026-04-23 20:00
CEBioForum 2026 is a leading international biotechnology conference bringing together professionals from Central and Eastern Europe and beyond. With over 20 years of tradition, CEBioForum serves as a trusted platform for dialogue, partnership-building, and knowledge exchange across the life sciences ecosystem.

The two-day event will take place in the modern spaces of CIC Warsaw, located in the very center of the city, and will feature a comprehensive program including high-level panel discussions, keynote presentations, startup pitch sessions, an exhibition area, and structured B2B networking supported by a dedicated event app. An evening networking reception and the CEBioForum Awards ceremony will further strengthen opportunities for meaningful connections.

The conference agenda will focus on the most relevant trends and challenges shaping the future of biotechnology and life sciences, including biotech and pharma innovation, medtech, clinical trials, data and AI in healthcare, venture capital and financing in CEE, cross-border collaboration, dual-use technologies, and pathways for scaling European innovations to global markets, particularly the US.

CEBioForum 2026 is the place to discover the dynamic Polish and CEE biotech ecosystem, meet decision-makers, investors, entrepreneurs, and researchers, and explore opportunities for collaboration, investment, and growth in one of Europe’s fastest-developing life science regions.

More Info Here

Made by Cells - Biotech Forum
2026-04-29 08:00 - 20:00
Join our Director General Dr Claire Skentelbery in Finland!

Join us at the Hanaholmen Cultural Center in Espoo Finland for inspiring talks on Pharma & Diagnostics, Food, Pigments and Polymers, alongside valuable networking opportunities with leading biotech innovators and stakeholders. Discover cutting-edge advancements and collaborate to shape the future of biotechnology. The event is organised in collaboration with VTT Technical Research Center of Finland

More Info Here

BioPharmaChem Impact 2026
2026-05-06 08:00 - 20:00
BioPharmaChem 2026 will bring together leading business leaders and experts on many pertinent topics including: realising the potential of the ecosystem, sustainability, digitalisation, the power of partnerships, resilient supply chains, the future of work, EU competitiveness and more.

Delegates will enjoy unmissable networking opportunities to connect with many biopharmaceuticals, pharmaceuticals and chemicals professionals in our bespoke exhibition area.

The Awards Dinner will honour excellence in the BioPharmaChem sector and celebrate the remarkable contributions and innovations that are shaping the future of our industry. This will provide a fitting end to a truly engaging event.

More Info Here

EFGCP Conference 2026
2026-05-12 08:00 - 2026-05-13 20:00
EuropaBio is supporting EFGCP Conference 2026.

Europe is at a defining moment for clinical research. The Clinical Trials Regulation set out a powerful vision: a continent united by transparency, collaboration, and efficient access to innovation. While its implementation brought both progress and pressure, it confirmed something essential—Europe’s commitment to ethics, quality, and patient protection remains unwavering.

National ethical review is a vital strength of Europe’s clinical research landscape. Ethics committees play a key role in ensuring trials uphold human dignity, scientific integrity, and public trust. Their contribution, together with the regulatory authorities’ risk-benefit review, forms the foundation of a credible and high‑quality research ecosystem. By further strengthening the collaborative partnership, Europe can achieve an ethical review process that is both protective and efficiently aligned with the needs of modern clinical research.

Today, national ethical review stands at the centre of the conference discussion. Ethics committees face growing complexity; sponsors navigate longer reviews and more information requests. These challenges highlight not failure, but opportunity: the chance to rethink how Europe aligns ethical excellence with operational efficiency.

In addition, the European Commission’s proposed new Biotech Act offers a fresh pathway—clearer roles, streamlined processes, and modern ethical standards grounded in the 2024 Declaration of Helsinki. It invites us to shape a system worthy of Europe’s innovation leadership ambitions.

The EFGCP Conference 2026 is where this work begins. Here, stakeholders from across Europe come together to share best practice experiences, challenge assumptions, and co‑create practical solutions to optimise the system. Our goal is simple and ambitious: to strengthen participant protection while enabling efficient, faster, more predictable clinical trial authorisations and start up times.

Together, we have the opportunity to build an ethical review model that reflects Europe at its best—responsible, collaborative, transparent and ready to lead the next chapter of global research.

More Info & Registration Here

EU Pharmaceutical Law Forum 2026
2026-05-19 08:00 - 2026-05-21 20:00
We are thrilled to announce our partnership with the EU Pharmaceutical Law Forum, one of the most significant events for legal and compliance professionals in the pharmaceutical industry.This forum is a cornerstone for discussing the latest developments in EU pharmaceutical law, regulatory frameworks, and compliance strategies. It brings together industry leaders, legal experts, and policymakers to address critical challenges and opportunities, shaping the future of healthcare and pharmaceuticals in Europe.As part of our partnership, we are delighted to offer 15% off registration* to our audience! Don’t miss this opportunity to gain valuable insights, network with key stakeholders, and stay ahead in the ever-evolving pharmaceutical landscape.

*This discount is applicable to Life Sciences Manufacturers only. Other restrictions may apply.

Discount code: EUPLEUBIO26

More Info Here

ECRD 2026: Rare Diseases in a changing & Competitive Europe
2026-06-03 08:00 - 2026-06-04 20:00
ECRD is the largest, patient-led policy-shaping conference for rare diseases in Europe. The event is an instrumental tool for advancing policy objectives that improve the lives of people living with a rare disease. The overarching title of ECRD 2026 is: Rare Diseases in a Changing & Competitive Europe: Shaping policies to address the unmet needs of people living with rare diseases.

Rare disease research has long driven breakthroughs in more common conditions, reinforcing Europe’s role as a global leader in biotechnology and precision medicine. Investing in this field is not only a moral imperative—it is a strategic move to boost Europe’s competitiveness in the life sciences. This is especially crucial in the context of the deployment of the Life Science Strategy and of the adoption of the Biotech Act.

More Info Here

Bio Innovations Europe 2026
2026-06-10 08:00 - 2026-06-11 20:00
EuropaBio is joining Bio Innovations Europe 2026 as a Headline Partner.

Taking place on 10-11 June 2026 in The Hague, the event—formerly known as World Bio Markets—has seen exponential growth. Since its 2022 relaunch, pre-arranged meetings have surged from 160 to over 1,050 in 2025—a 550% increase. The 2026 edition is set to be the largest yet, hosting more than 400 attendees and facilitating 1,500 commercial meetings between bio-developers & producers, chemical manufacturers, consumer brands & intermediates, community enablers, investors & financiers and suppliers.

Delivering the Biotech future of Europe: EuropaBio at Bio-Innovations

EuropaBio, the industry association that champions innovative bioindustries, is proud to host a dedicated programme together with partner Bio-Innovations.

EFIB presents Europe’s key opinion leaders, bringing a clear statement to legislators at EU and national levels. 2026 brings legislation for simplification, defragmentation and acceleration of biotechnology as a vital global technology and Europe must ensure that it can compete in the global race to dominance for biotechnology and biomanufacturing.

In addition to an opening keynote, where the 2026 EFIB Statement will be launched, EuropaBio, through its EFIB platform, will also host dedicated workshops:

Executive Round Table: Senior stakeholders from across the corporate, policy and scientific community will discuss the priorities for Europe in 2026 and the ambition that must be delivered through legislative programmes that include the Bioeconomy Strategy, Biotech Act and Food and Feed Safety Omnibus, in addition to industrial policy levers including the European Competitiveness Fund, EU Inc. and STEP regulation.

SME Breakfast: The engine of innovation, the SME breakfast will bring together the entrepreneurs that translate Europe’s research excellence into products, delivering economic growth and supply chain resilience. The meeting will discuss their challenges and needs, resulting in the 2026 SME Statement for Industrial Biotechnology, published following the conference.

25% discount for EuropaBio’s network: BIEUEB

More Info Here

European Biotech Forum 2026
2026-06-11 09:00 - 13:30
EuropaBio is a proud sponsor of the European Biotech Forum 2026.

Biotechnology is becoming a decisive capability for Europe’s competitiveness, industrial resilience and strategic autonomy. But Europe enters the next institutional cycle with a fragmented policy landscape, uneven regulatory capacity, and persistent scale-up barriers. The Commission’s Biotech Communication I and Biotech Communication II set out an initial toolbox, but fall short of an end-to-end industrial framework comparable to the US. The gap between ambition and execution remains significant. To what extent do these communications address the core challenges of Europe’s biotech sector? Where are the structural gaps that still block growth and industrial deployment?

More Info & Registration Here

Preparing for scale: industrial readiness and infrastructure access
2026-06-25 13:00 - 14:00
APROVALS Webinar Series – Public Session

This is the first session of the APROVALS public webinar series, a programme of collective learning events open to companies participating in the project and to the broader industrial ecosystem.

APROVALS webinars are designed to go beyond individual sandbox sessions: they create a shared space where companies can compare experiences, discuss cross-cutting challenges, and engage with external experts on the topics that matter most to scaling innovative technologies.

Session #1 – Preparing for scale: industrial readiness and infrastructure access

One of the most strategic — and most frequently asked — questions among APROVALS participants: how do you know when you are ready to move from pilot to industrial scale?

This session will explore:

The key signals and criteria that indicate readiness for industrialisation

Common bottlenecks companies face when scaling from lab or pilot to full production

Frameworks and options available to navigate this transition in a structured way

We’ll discuss with:

Rob Kooijmans (Food Safety)

Reza Ranjbar (AartinBio)

More Info Here

EuropaBio Biomanufacturing Policy Summit 2026
2026-07-01 09:30 - 13:30
From legislation to impact for Europe

Biomanufacturing lies at the heart of Europe’s future societal and entrepreneurial strength and is changing the business landscape for both emerging innovators and established industry champions.

EuropaBio’s 4th Biomanufacturing Policy Summit will focus on how legislation delivers impact within a proactive Biomanufacturing strategy, and how we establish EU targets for outcomes. It will also showcase the 2026 update of the EuropaBio WIfoR study ‘Measuring the Economic Footprint of the Biotechnology Industry in the European Union’ prior to full report launch in September.

The prize is globally competitive multi-sector biomanufacturing, keeping pace with industrial transition in major global regions and securing Europe’s supply chains, healthcare future, decarbonisation and economic resilience.

This meeting will bring together EuropaBio Members, representatives of key sectors, plus national and EU stakeholders across institutions.

This event will be accessible by invitation only, for more information contact us at: communications@europabio.org and c.skentelbery@europabio.org

EFIB Den Haag Statement - A modernised European Union for Industrial Biotechnology
2026-07-13 10:00 - 11:00
EuropaBio’s EFIB Statement presents three clear asks for the European Union:

Ask 1 – Modernising regulation and policy: A dedicated, horizontal EU Regulation for Microorganisms

Ask 2 – Education and awareness: Future-looking stakeholder engagement and Representation

Ask 3 – Financing innovation: Delivering a mature funding and collaborative framework

These asks sit within a progressive legislative mandate for industrial biotechnology and microorganisms. It supports the translation of a competitiveness agenda into legislation that delivers the bioeconomy.

Join EuropaBio for a deep dive into the EFIB Statement and what it means for innovation and manufacturing in the European Union?

AGENDA

Presentation of the EFIB statement: Claire Skentelbery, Director General, EuropaBio

Fireside chat: Giovanni Colombo, Group Senior Director Public Affairs, dsm-firmenich and Board Member EuropaBio

Register Here

Prague.bio Conference 2026
2026-09-23 08:00 - 20:00
Join our Director General Dr Claire Skentelbery at the 4th edition of Prague.bio Conference!

If you want to meet and network with biotech leaders shaping the CEE region, Prague.bio Conference 2026 is the place to be

Expect 400+ participants, partnering via the conference app, inspiring keynotes, panel discussions, hands-on workshops, and pitch & poster sessions.

More Info Here & Tickets

World Orphan Drug Congress 2026
2026-10-26 08:00 - 2026-10-28 20:00
The World Orphan Drug Congress Europe is the largest and most established event globally for orphan drugs and rare diseases.

Join over 1,800 senior industry leaders, gain insights from 250+ expert speakers, and connect with over 100 exhibitors driving progress across the entire orphan drug lifecycle. From regulatory strategy and market access to patient engagement and the latest breakthroughs in gene and cell therapies, the congress delivers practical insights you can apply immediately.

Network with the most senior individuals across the industry, including leaders in R&D, gene therapy, rare diseases, precision/personalised medicine, genetic disorders, patient advocacy and engagement, associations in ATMPs, investors, regulatory affairs professions, governmental bodies, and more…

More Info Here
